Endothelial Rehabilitation: The Impact of Chronic PDE5 Inhibitors on Erectile Function and Protein Alterations in Cavernous Tissue of Diabetic Rats by Ling X De Young et al.
e u r o p e a n u r o l o g y 5 4 ( 2 0 0 8 ) 2 1 3 – 2 2 0
avai lab le at www.sciencedi rect .com
journa l homepage: www.europeanurology.comSexual Medicine
Endothelial Rehabilitation: The Impact of Chronic PDE5
Inhibitors on Erectile Function and Protein Alterations in
Cavernous Tissue of Diabetic RatsLing X. De Young a,b, Trustin Domes b,c, KokBin Lim d, Jeffery Carson a,c, Gerald B. Brock a,b,c,*
a Lawson Health Research Institute, London, ON, Canada
b St. Joseph’s Health Care, Department of Surgery, Division of Urology, London, ON, Canada
cThe University of Western Ontario, London, ON, Canada
dSingapore General Hospital, SingaporeArticle info
Article history:
Accepted February 28, 2008
Published online ahead of














Background: Diabetic men generally have reduced efficacy with PDE-5 inhibitors
(PDE5i) for the treatment of erectile dysfunction (ED).
Objective: To determine whether chronic vardenafil exposure alters cavernous protein
expression predicting improved erectile function in diabetes.
Design: Forty-two adult male Sprague Dawley rats with streptozotocin-induced
(50 mg/kg IP) diabetes for 4 wk, were exposed to either vehicle or vardenafil for
6 wk. Assessments compared the impact of vardenafil given at 1 h and 20 h to erectile
function and cellular alterations and downstream translation of cavernous protein
profiles were aimed.
Intervention: Vehicle or vardenafil 0.5 mg/kg/day by oral gavage for 6 wk.
Measurements: Erectile function, penile tissue morphology, protein expression and
surface enhanced laser desorption/ionization time-of-flight mass spectrometry
(SELDI) protein profiling were determined.
Results and Limitations: A significant increase of intracavernous pressure was seen in
both treatment arms compared to diabetic rats not receiving vardenafil. Immunohis-
tochemical staining showed improved endothelial and smooth muscle cell staining
with chronic vardenafil use. Western blot analysis demonstrated increased endothe-
lial cell eNOS and smooth muscle a-actin protein content. SELDI protein profiling
showed enhanced proteins expression at molecular weights of 14.7, 20, 41.9, 66.2, and
83.9 kDa in the chronically treated vardenafil group.
Conclusions: Vardenafil was effective in treating diabetic-induced ED with the greatest
effect achieved through chronic dosing, with no additive effect measured with the final
acute dose. Changes noted in the histology and protein expression indicate that
vardenafil may have a protective effect in this disease state. This finding may serve
work evaluating the utility of chronic vardenafil dosing in diabeticwww.eu-acme.org/
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Erectile dysfunction (ED) is common in the diabetic
population. Diabetic men suffer from ED at a
younger age and with a greater frequency compared
to nondiabetics, with prevalence rates of 20% to 75%
[1]. Normal erectile function requires intact neural
and vascular pathways, both of which are impaired
in diabetes. Nitric oxide (NO) production, the key
process of a normal erection, is primarily affected by
diabetes-induced endothelial dysfunction [2]. Addi-
tionally, hyperglycemia leads to oxidation of low
density lipoprotein and increased production of
free-oxygen radical species, leading to smooth
muscle dysfunction [3]. Direct inactivation of NO,
largely by a superoxide anion believed to be present
in higher than normal concentrations in diabetes,
may also play a role in producing impaired caver-
nosal relaxation and ED [4].
Initiation of penile erection is dependent on
release of NO from penile distal nerve terminals,
which stimulates the production of cyclic GMP
(cGMP) and results in smooth muscle relaxation.
cGMP is normally metabolized by the cGMP-specific
type 5 phosphodiesterase (PDE5), which is the major
isozyme metabolizing cGMP in the corpus caverno-
sum. Inhibition of PDE5 potentiates the cGMP
smooth muscle relaxing signal and is a proven
pharmacologic agent for the treatment of ED across
a broad range of etiologies and ages [5]. Although the
efficacy of PDE5 inhibitors (PDE5i) in a general
population is 70%–89%, only 50% of diabetic men
with ED respond favorably [6]. This relative treat-
ment resistance to PDE5i has sparked new research
to develop strategies to treat diabetic men with ED. It
is hypothesized that chronic daily dosing of PDE5i
may act through enhancing endothelial rehabilita-
tion in vascular causes of ED, as shown in human
and animal models [7–9]. The efficacy and mechan-
ism by which this strategy may impact diabetic
patients with ED has yet to be elucidated. This study
utilizes a diabetic rat model to gain further insight
into the questions of whether chronic PDE5 inhibitor
exposure alters cavernous protein expression andFig. 1 – Animal dwhether these changes lead to improved erectile
function.
2. Materials and methods
2.1. Diabetic animal model
Forty-two adult male Sprague Dawley rats aged 20–24 wk
received streptozotocin (50 mg/kg ip) in pH 4.5 citric acid
buffer to induce diabetes. Rats that tested positive for
hyperglycemia by tail vein sampling at 2 d were used in the
study. After a 4-wk conditioning treatment-free period, the
diabetic rats were assigned randomly to an experimental
group [Fig. 1]. Control 1 (C1) rats were studied for ED following
4 wk of diabetes, with 7 rats receiving an acute dose of
vardenafil (0.5 mg/kg) by oral gavage 1 h prior to erectile
function testing (C1/VD). Control 2 (C2) rats were given an
additional 6 wk of water gavage, with 7 rats receiving an acute
dose of vardenafil (0.5 mg/kg) by oral gavage 1 h prior to
erectile function testing (C2/VD). The treatment groups
composed of 7 rats in each arm, with both arms receiving
chronic vardenafil (0.5 mg/kg) by oral gavage daily for 6 wk but
erectile function testing was carried out either at 1 h (T) or 20 h
(T/VD) after the last dose of vardenafil.
2.2. Evaluation of erectile function
Erectile function was assessed via cavernous nerve electro-
stimulation as described previously [10]. Intracavernosal
pressure was evoked with 0.2 ms pulses of 2 mA at 20 Hz for
a 40 s duration and recorded using LabVIEW 7 Express
software (National Instruments, Austin, Texas). Three elec-
tro-stimulations were replicated at intervals of 10 m. All
treatments were stopped at least 20 h before evaluation of
erectile function. The final dose of vardenafil was given either
20 h preceding the electro-stimulation experiments for group
T or 1 h for groups C1/Vd, C2/Vd and T/VD.
The rats were sacrificed using pentobarbital (200 mg/kg iv)
and then penile tissue was harvested for analysis. The animal
experimental protocol was approved by the University Council
on Animal Care Animal Use Subcommittee, University of
Western Ontario, London, Canada.
2.3. Immunohistologic analysis
Penile tissue was fixed in cold fresh 2% formaldehyde, cryo-
protected in 30% sucrose, then embedded in OCT compoundistribution.
e u r o p e a n u r o l o g y 5 4 ( 2 0 0 8 ) 2 1 3 – 2 2 0 215(Tissue-Tek, Sakura,USA) and stored at 70 8C as described
previously [10]. 5 mM sections were immunostained with
primary antibody: neuronal nitric oxide synthase mouse
anti-nNOS, endothelial cell marker mouse anti-CD31 (Trans-
duction Lab Mississauga, Canada), mouse anti-a-actin (Lab
Vision, Fremont, CA), secondary antibody biotin conjugated
goat anti-mouse IgG (Sigma, St.Louis, MO, USA), and anti-
biotin clone BN-34 peroxidase conjugate IgG fraction (Sigma)).
Histologic examinations were performed using a Zeiss
microscope with a computerised imaging system (Northern
Eclipse, Empix, Canada) by a blinded reviewer. Positive
staining of nNOS in dorsal nerve was counted. Positive
staining of CD31 within the major penile sinusoidal lining
was measured under 400 power. The area of positive staining
of smooth muscle a- actin was calculated as the ratio of total
sectional area under 25 power in 4 duplicate sections of each
sample.
2.4. Protein preparation
The inner layer of penile crus was harvested under optical
magnification and washed, frozen on dry ice, and stored at
70 8C. Frozen tissue was thawed and washed once with red
blood cell lysis buffer and PBS. The pellet was homogenized in
a small volume of tissue protein extracting buffer (pH 7.2,
Pierce, Rockford, Illinois, USA) supplemented with protease
inhibitor (Roche, Penzberg, Germany). All procedures were
carried out on ice using an Ultra Turrax homogeniser at high
speed. Insoluble material was pelleted by centrifugation
(10,000 rpm, 5 m, 4 8C). The soluble fraction was collected
and protein concentration was determined by using a BCA
protein assay according to the manufacturer’s protocol
(Pierce, Rockford, Illinois, USA).
2.5. Protein expression profiling
Proteins were analyzed using surface enhanced laser desorp-
tion/ionization time-of-flight mass spectrometry (SELDI-
TOF-MS, Ciphergen Biosystems, Fremont, CA, USA). A CM10
(weak cation-exchange) protein chip 8-spot array was pre-
washed with 50ul of pH 4 0.1 M sodium acetate binding buffer
for 5 m on a shaker, 5 mg of protein was added to the
designated spots of a CM10 chip with 95 ml binding buffer
using a bio-processor and incubated at RT for 1 h with vigorous
shaking on DPC MicroMix5 (DPC Los Angeles, CA). The protein-
bound CM10 arrays were then washed and air-dried. Each spot
was spotted with 1 ml of a saturated solution of sinapinic acid
(50% acetonitrile, 0.5% trifluoroacetic acid) (Sigma) and
repeated once. Dried protein chips were placed in the SELDI
ProteinChip System Series 4000 Reader using an automated
data collection protocol.
2.6. Western blotting
5 mg of protein was separated on 10% polyacrylamide gel
electrophoresis and transferred to Hyboud-ECL nitrocellulose
membrane (Amersham, Piscataway, NJ, USA). Mouse anti
smooth muscle a-actin, eNOS, caveolin-1 and b-actin were
used as primary antibodies. Goat anti-mouse horseradish
peroxidase-conjugated IgG) (Santa Cruz, CA) was the second-ary antibody. Antibody specific bands were detected using
enhanced chemiluminescence (ECL) reagents (Amersham
Biosciences) visualized and analysed by using Chemi Genius2
Gel Documentation System (PerkinElmer, Quebec, Canada).
Each densitometric value was normalized against the loading
control of b-actin densitometric value.
2.7. Statistical analysis
Values are expressed as the mean plus and minus standard
error of 7 experiments for each group. Data were compared
using one way ANOVA. SELDI-TOF-MS spectra were normal-
ized on total ion current, with normalization coefficients 95%
confidence interval. Subsequently, each spectrum was ana-
lyzed using the Ciphergen ExpressTM 3.0 software, Biomarker
Wizard.
3. Results
3.1. Body weight, serum triglycerids, and cholesterol
The animals in all six groups showed persistent
hyperphagia, polydipsia, and polyuria consistent
with poorly controlled diabetes. No differences in
body weight or degree of hyperglycemia were
measured between control and treatment groups.
Interestingly, in spite of similar elevations in glucose
levels between C1 and C2, the serum triglyceride
levels were significantly higher in C2, which may
reflect the extended study period of this group. The
vardenafil treatment group showed lower concen-
trations of serum triglycerides compared with C2,
but did not reach statistical significance due to high
internal variability among samples in the C2 group
[Table 1].
3.2. Penile response
The area under the curve of penile intracavernous
pressure (ICP) following electro-stimulation of the
cavernous nerve is depicted in Fig. 2. Penile
pressures (PP) at 4 wk (C1) and 10 wk (C2) were
2085  143 and 2218  1 64, compared with
3542  231 (C1/Vd), 2942  189 (C2/Vd) ( p < 0.05)
with a single dose of vardenafil 1 h before the
erectile function test. Following 6 wk of daily
vardenafil, PP were 3223  193 (T) and 3321  1
89 cmH2O second (T/Vd). There was no additional
increase of ICP with an acute dose of vardenafil
(T/VD). The 10-wk diabetic rats had a smaller
increase in PP following an acute dose vardenafil.
3.3. Immunohistologic results
There was no difference of nNOS staining among the
control and treatment groups, therefore the results
Table 1 – Body weight, serum triglycerides and cholesterol
C1 (4 wk) C2 (10 wk) Treatment (10 wk)
Body weight (g) 429.5  4.8 434.2  3.9 424.9  2.9
Serum triglycerides (mM/l) 2.15  0.9* 5.56  2.3* 2.99  0.8
Serum cholesterol (mM/l) 1.34  0.1 1.06  0.9 1.24  0.1
* p < 0.05, C1 compared with C2.
Fig. 2 – Penile pressure measured in response to electro-
stimulation of the cavernous nerve. Bar graph shown the
ICP area under curve obtained from seven animals in
triplicate of mean W SE. A significant difference was
measured between diabetic animals (C1,C2) and diabetic
animals exposed to an acute (C1/Vd, C2/Vd) or chronic
(6 wk) dose of vardenafil.
Table 2 – Summary of immunohistological results
C1 C2 Treatment
% Endothelial cell (CD31) 21.8  6.4 22.8  8.7 50  9.3*
% smooth muscle a-actin 6.6  1.0 6.1  0.9* 8.4  0.8*
The proportion of positive staining of endothelial cell marker CD31
within the major penile sinusoids (power 400) was significantly
increased in the treatment group. The proportion of positive
staining of smooth muscle a-actin to the cross-sectional area
(power 25) was significantly increased in the treatment group
compared with C2. *p < 0.05.
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significantly higher positive staining for a-actin
compared to the 10-wk nontreated diabetic rats
(C2) [Table 2].
Penile cavernosum sinusoidal endothelial cell
staining was altered in all groups to varying degrees.
Among the animals receiving vardenafil, greater
intensity of endothelial marker CD31 was measured
[Fig. 3]. The proportion of positive staining of CD31Fig. 3 – Representative slides of immunostaining of corpora cav
positive staining (dark brown) in the endothelium lining the ca
control (power 400T).within the major penile sinusoidal lining was
significantly increased in the treatment group
[Table 2].
3.4. Western blot results
Western blot analysis of smooth muscle a-actin,
eNOS and caveolin-1 from penile tissue extracts
demonstrated strong bands of 40 kDa (smooth
muscle a-actin) and 140 kDa (eNOS) in treatment
groups compared with C2 [Fig. 4]. There was a
significant increase of densitometric value of both
smooth muscle a-actin and eNOS in the treatment
groups and this was supported by the immunohis-
tologic results. These results indicate that PDE5i
have a positive impact in preventing endothelial cell
damage and preserving smooth muscle content,
which is proportional to the preservation of erectile
function.ernosa with endothelial cell marker CD31. Note the strong
vernous sinusoid in the treatment group compared to
Fig. 4 – Western blot analysis of penile tissue extracts. Left blot shows 140 kDa eNOS, 40 kDa smooth muscle a-actin, 22 kDa
Caveolin-1, and 42 kDa b-actin (protein loading control). Right panel shows the percentage of protein densitometric value
over b-actin of 7 penile tissue extracts from each group. The treatment group demonstrated higher expression of a-actin,
eNOS content and eNOS/Caveolin-1 (e/Cave) *: p < 0.05.
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SELDI mass identification was performed by aver-
aging a minimum of 10 laser shots at the laser
intensity of 4000 to various regions of the protein
chip surface. Fig. 5 compares the gel spectral view of
proteins from C2 and the treatment group, with
masses ranging from 35 to 75 kDa. Increased
intensity of the 41.9 kDa protein peak in the
treatment group was observed [Table 3].4. Discussion
Diabetes is a systemic disorder resulting in meta-
bolic derangements leading to eventual end organFig. 5 – Gel spectral view of the SELDI penile tissue protein profi
Treatment group (right). Spectra from 35 to 75 kDa demonstrate
protein moiety in the Treatment group compared with C2 groudamage, including ED. Prolonged periods of high
circulating serum glucose increase the concentra-
tion of free oxygen radicals and advanced glycosyla-
tion end products, which may lead to vascular and
neural impairmen [11]. Penile erection is dependent
on intact vascular and neural pathways, which
become deranged in diabetes, making diabetes a
significant risk factor for development of erectile
dysfunction. Unfortunately, the clinician treating
diabetic men with erectile dysfunction has few
evidence-based studies to support strategies
designed to adequately prevent and treat diabetes-
induced ED, apart from recommending tight blood
sugar control.
PDE5i are first-line oral therapy for the manage-
ment of ED across a wide range of aetiologies andle using the CM10 chip array. Six samples from C2 (left) and
s an increased intensity of molecular weight 41.9 kDa
p.
Table 3 – SELDI protein profile
M/Z kDa C2 Treatment P-Value
14.7 167  56 269  64 0.013
20.0 6.6  2 11.7  8.7 0.034
41.9 3.4  1.2 5.6  1.9 0.025
66.2 5.8  1.3 7.5  1.3 0.034
83.9 0.4  0.2 0.7  0.2 0.013
The SELDI protein intensity profile of Control 2 (C2) vs. treatment
(T) group. Each spectrum was analyzed using the Ciphergen
ExpressTM 3.0 software, Biomarker Wizard.
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90% of ED patients choose PDE5i as their primary
treatment [12,13]. Sildenafil, tadalafil, and vardena-
fil have all undergone extensive testing and have
consistently demonstrated good response rates in
most cohorts of patients. However, diabetic men
with ED tend to have an impaired PDE5i response
compared to other cohorts in clinical trials [14].
Epidemiologic studies have shown an increasing
prevalence of obesity [15,16], making diabetes-
associated ED a possible epidemic in North America.
Therefore, there is a need to develop new treatment
strategies for men suffering with diabetes-asso-
ciated ED.
In this study, we explored the potential effect of a
PDE5i, vardenafil, on the erectile mechanism utiliz-
ing a diabetic rat animal model. We wanted to
answer the following question: Does acute versus
chronic exposure to PDE5i in diabetes have measur-
able differences in erection quality, and if so, can
protein analysis identify a biomarker responsible for
this effect? We showed that vardenafil had affects
on more than just erectile function. In this animal
model, rats that were diabetic for 10 wk had higher
triglyceride levels than those that were diabetic for 4
wk. Additionally, vardenafil-treated rats had lower
serum triglyceride levels compared to rats not
receiving the drug, which supports a previously
reported observation [10]. There are also reports that
another PDE inhibitor, the PDE3i (cilostazol),
improves endothelial function and reduces serum
triglyceride levels in animals and in human clinical
trials [17,18] by increasing cAMP and PKA signaling.
Epidemiologic studies demonstrate that men with
ED are at a higher risk of having dyslipidemia,
including hypertriglyceridemia [19] and animal
study implicated hypertriglyceridemia as a potential
etiology of ED [20]. The clinical significance of the
PDE5i effect on lipid profile remains to be answered.
Diabetes-associated ED is a complicated patho-
logical process that affects erectile function at a very
early stage [10,21] There is abundant evidence to
support the theory that endothelial cell damage is
the primary cause of diabetes-associated ED [22,23].This was supported in our study, where the diabetic
control rats showed a significant loss of cavernous
sinusoidal endothelial lining by immunohistologic
staining and protein contents by western blot
[Table 2, Figs. 3 and 4]. There was a protective effect
demonstrated in rats receiving daily vardenafil, with
improved endothelial and smooth muscle cell
staining on immunohistochemistry [Table 2, Fig. 3]
and increased endothelial cell eNOS and smooth
muscle a-actin protein content on western blot
analysis [Fig. 4]. Our findings are consistent with
those of Schäfer et al, who reported that chronic
treatment of diabetic rats with sildenafil resulted in
a significant improvement of endothelium-depen-
dent as well as -independent vasorelaxation, even
more than 24 h after the last dosing [24]. Addition-
ally, chronic usage of PDE5i may also benefit the
host across a wide range of nonvascular therapeutic
indications such as high altitude sickness to
Peyronie’s disease [25]. As expected, rats that
received vardenafil, either acutely or chronically,
had significantly improved ICP compared with
control rats. Erectile and endothelial parameters
were enhanced with chronic PDE5i administration
by other study [26].
Interestingly, we were not able to demonstrate a
further increase in ICP with chronic vardenafil
treatment compared with a single acute dose. This
finding was also reported by Behr-Ross’s group
using normal rats with daily Sildenafil for 8 wk [27].
However, we were able to demonstrate that rats
with diabetes for only 4 wk had a better response
(improved ICP with electro- stimulation) compared
to rats with diabetes for 10 wk. This finding supports
our current understanding of the pathophysiology
of diabetes, where erectile function declines as
diabetes progresses.
The eNOS pathway plays a critical role in the
physiology of penile erection. Endothelium Nitric
Oxide Synthase (eNOS) is negatively controlled by
Caveolin-1, a 22 kDa protein that is ubiquitously
expressed and abundant in endothelial cells [28].
Caveolin-1 inhibits eNOS through two mechanisms:
First, it impedes the signaling of caveolae-targeted
receptors that transfer eNOS-stimulatory signals,
and second, it blocks the calmodulin-binding site of
eNOS [29]. Caveolins play a dynamic role in the
trafficking of proteins on membranes and regulating
signaling molecules in disease conditions in which
Caveolins have been implicated, including athero-
sclerosis, hypertension, cardiomyopathy, diabetes,
and oncogenesis [30]. In this study, there was
no difference of Caveolin-1 expression in both
control and treatment groups. However, the rats
receiving chronic vardenafil (treatment group) had a
e u r o p e a n u r o l o g y 5 4 ( 2 0 0 8 ) 2 1 3 – 2 2 0 219statistically higher ratio of eNOS/Caveolin-1. This
reflects a higher eNOS content in the treatment
group and a higher capacity to overcome the
negative inhibition of Caveolin-1.
One of the novel and exciting aspects of this study
was the discovery of differential protein expression
between the control rats and those exposed to
Vardenafil chronically for 6 wk [Table 3, Fig. 5].
Although these are preliminary results, these
proteins could represent biomarkers that may help
to prognosticate treatment affect with PDE5i in
patients with diabetes-associated ED. Further work
is needed to identify these useful markers in the
hope that they may give us insight on how to
manage this difficult to treat subset of men with ED.5. Conclusions
This is the first report describing the effects of
chronic vardenafil exposure in a diabetic animal
model evaluating physiologic, morphologic, and
protein changes as they relate to erectile function.
Chronic use of the PDE5 inhibitor vardenafil for 6 wk
significantly improved erectile function in this
diabetic rat model. These physiological changes
were further supported by penile cavernosal tissue
protein expression of increasing eNOS and smooth
muscle a-actin protein content and the upregulation
of protein species on a proteomic assay compared to
untreated diabetic rats.
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